Evaluation of a Polyherbal Formulation on the Management of Migraine Headaches due to Functional Dyspepsia: A Double-Blind, Randomized, Placebo-Controlled Clinical Trial

Table 3

The effects of different interventions on HIT-6 and FD scores at week 0 and week 12.

Group no.	Score		value	∆(W12–W0) score
	HIT- 6
	Week 0	Week 12
1	65.86 ± 2.43	56.17 ± 4.59		9.69 ± 4.62
2	65.62 ± 2.02	55.59 ± 4.39		9.69 ± 4.39
3	66.45 ± 2.75	56.27 ± 4.96		10.18 ± 4.46
value	0.88	0.87
	FD score
	Week 0	Week 12
1	8.86 ± 2.66	4.69 ± 1.98		4.17 ± 2.01
2	8.43 ± 2.48	5.95 ± 1.79		2.47 ± 1.56
3	8.90 ± 2.02	5.13 ± 1.85		3.77 ± 1.77
value	0.88	0.11

Data were presented as mean and standard deviation (SD). value was calculated by the Wilcoxon test; value was calculated by Kruskal-Wallis. Group1: the polyherbal formulation capsule 1500 mg (two capsules of 750 mg) three times a day, + Depakine® tablet 200 mg twice a day + Amitriptyline tablet 10 Mg once a day; Group2: Depakine® tablet 200 Mg twice a day + Amitriptyline 10 mg once a day + the polyherbal formulation placebo capsule three times a day; Group3: the polyherbal formulation capsule 1500 mg (two capsules of 750 mg) three times a day + Depakine® placebo tablet twice a day.